Background: Unlike other breast cancer subtypes that may be treated with a variety of hormonal or targeted therapies, there is a need to identify new, effective targets for triple-negative breast cancer (TNBC). It has recently been recognized that membrane potential is depolarized in breast cancer cells. The primary objective of the study is to explore whether hyperpolarization induced by opening potassium channels may provide a new strategy for treatment of TNBC. Methods: Breast cancer datasets in cBioPortal for cancer genomics was used to search for ion channel gene expression. Immunoblots and immunohistochemistry were used for protein expression in culture cells and in the patient tissues. Electrophysiological patch clamp techniques were used to study properties of BK channels in culture cells. Flow cytometry and fluorescence microscope were used for cell viability and cell cycle studies. Ultrasound imaging was used to study xenograft in female NSG mice. Results: In large datasets of breast cancer patients, we identified a gene, KCNMA1 (encoding for a voltage-and calcium-dependent large-conductance potassium channel, called BK channel), overexpressed in triple-negative breast cancer patients.
Background
The main molecular subtypes of breast cancer are termed Luminal A (ER+/HER2-), Luminal B (ER+/HER2+/-, higher histological grade, more aggressive than Luminal A), HER2enriched (ER-/HER2+), and triple-negative (ER-/PR-/HER2-) [1] . Recent gene expression studies further identified five "transcriptional subtypes" of breast cancer: basal-like, HER2-enriched, luminal A, luminal B, and normal-like (now thought not to originate from breast cancer) [2] . Up to 70% of triple-negative breast cancer (TNBC) have the basal-like gene expression signatures, however, a large number of basal-like tumors express ER, PR or HER2 [3] . Further studies on molecular signatures, genetics, and genomics have led to the identification of four TNBC subtypes (basal-like 1, basal-like 2, mesenchymal, and luminal androgen receptor) [4, 5] . These studies have revealed the complexity of breast tumors and generated many new hypotheses for potential therapeutic targets for treatment of TNBC.
TNBC is one of the subtypes of breast cancer with an earlier onset, more aggressive metastasis, and lacks the therapies available to ER+, PR+, and HER2+ breast cancers [3] .
Five-year breast cancer survival is significantly reduced with diagnosis of TNBC [6] , due largely to relatively ineffective therapeutic options [7] . There is therefore a need to identify new, effective targets for TNBC.
All cells maintain a polarized membrane potential (Em), more negative inside than outside the cell membrane. Em is essential to the development of action potentials in excitable cells such as neurons and cardiac myocytes. However, accumulating evidence has also demonstrated variability of Em in non-excitable epithelial cells and cancer cells as well [8] . Alterations in Em (depolarization -i.e. Em becoming more positive, hyperpolarization -Em becoming more negative) are now recognized to play a crucial role in controlling the cell cycles [9, 10] .
Using a traditional microelectrode technique, Em was reported to be -13mV in breast cancer biopsy specimens from nine women with infiltrating ductal carcinoma, independent of ER or PR presence [11] . For comparison, normal human breast epithelial cell Em is near -60mV [11] . Thus, Em is depolarized in breast cancer compared to normal breast cells.
Using whole-cell patch clamp, we found more positive Em in TNBC MDA-MB-231 cells (-39.5mV ) than in normal breast cells (-66.9 mV) [12] . KCNMA1 gene encodes the pore-forming alpha subunit of a voltage-and calcium-gated large-conductance potassium channel, called BK (also known as Slo1, Maxi-K, or KCa1.1) channel [13, 14] . Previous studies have suggested a contradictory role of KCNMA1 in breast cancer proliferation, invasion, and metastasis. Blockade of BK channels can slow proliferation and invasion of breast cancer cells [15, 16] . In contrast, studies with antitumor compounds revealed anti-tumor action as an important result with activation of BK channels in metastatic breast cancer cells [17] . BK In this work, we present evidence for overexpression of KCNMA1 in TNBC from a large dataset. Second, we verify a significant increase in protein expression of BK channels in TNBC cell lines and primary TNBC tissues. Third, we provide an answer to an intriguing question regarding how breast cancer cells remain depolarized while overexpressing a hyperpolarizing ion channel, which should make cell membrane potential more negative.
Fourth, we demonstrated that opening BK channels hyperpolarizes Em and induces apoptotic death of TNBC cells via apoptosis. Fifth, we show that BK channel openers can slow tumor growth in an MDA-MB-231 xenograft model in female NSG mice to validate the main in vitro finding. Finally, we show that this new approach of using BK channel openers for selective induction of death in TNBC does not impact healthy breast tissue and cardiac function. 
Methods

KCNMA1 gene expression in The Cancer
Live cell imaging
Live cell imaging experiments were performed using a Zeiss Axio Observer A1 inverted microscope with fluorescence. Images were acquired and analyzed using AxioVision (version 4.6). We used ethidium homodimer-1 (EthD-1, Invitrogen, 0.2-0.5ml of 2mM stock to 1ml culture of cells in 6-well plates) to label dead cells. Cell count was performed using ImageJ (NIH).
Western blotting
Cells were harvested using Radioimmunoprecipitation Assay (RIPA) buffer with 1% protease inhibitor cocktail (Sigma). We then sonicated lysates on ice and centrifuged at 12,000xg for 10 minutes at 4 o C. Tumor tissue was homogenized in RIPA buffer with 1% protease inhibitor cocktail (Sigma), then centrifuged at 12,000xg for 10 minutes at 4 o C.
Supernatant was isolated from debris pellet.
Protein concentration was measured using Bicinchoninic acid assay (BCA) (Thermo Fisher).
Once protein concentrations were normalized across samples, they were then heated for 12 minutes at 90 o C. Samples were loaded into NuPage 4-12% bis-tris gels (Invitrogen) with MOPS running buffer at 70 volts for 100 minutes, then transferred to 0.2 mm pore PVDF membrane (Thermo Scientific) at 30 volts for one hour in cold room. Next, blots were blocked in Licor blocking buffer for one hour, and incubated for 12 hours at 4 degrees with primary antibody for either anti-KCNMA1 for epitope 199-213 (Alomone cat# APC-151), anti-caspase-3 (Cell Signaling Technology), or anti-Slo1 for c-terminus segment 9-10 (Millipore) at 1:500 dilution. The membrane was then washed 3 times for 15 minutes with tris-buffered saline containing 0.1% tween-20 (TBS-T). A secondary antibody, IR 800 CW from Licor (1:20,000 dilution) was incubated with the membrane at room temperature for one hour. After three 10-minute washes with TBS-T, blots were imaged using a Licor Odyssey CLx and image studio software. If residual background signal was observed, additional washes of 5 to 10 minutes with TBS-T were completed and the membrane was re-imaged. Beta-actin primary antibody (Proteintech) and IRDye 680RD secondary antibody (Licor) were used as a loading control.
Immunohistochemistry of patient breast samples
Experiments involving patient breast samples were approved by West Virginia University Institutional Review Board. Formalin-fixed paraffin-embedded (FFPE) breast tumor tissue from patients was processed according to vendor's manual instruction (Biocare) and following a verified protocol in the Pathology Laboratory of Translational Medicine at WVU.
Briefly, 3mm sections were deparaffinized on slides, quenched with hydrogen peroxide, and incubated in BK channel antibody (Sigma-Aldrich, HPA054648) Sigma at 4 o C for 4 minutes. Horseradish peroxidase-containing secondary antibody (UMap anti-RB, Roche, Diagnostic, Cupertino, CA) was then added for 8 minutes and developed using Biocare DAB (brown color). Hematoxylin was used as a counterstain (blue color).
Automated formalin-fixed, paraffin embedded immunohistochemical staining, to evaluate tumor antigen expression profiles, is available via the Ventana DISCOVERY automated IHC Platform. Breast tumor IHC slides stained with BK channel antibody were examined under an Olympus VS-120 slide scanner with a 10X Plan S Apo/0.40 NA objective, equipped with a color camera (Pike 505C VS50). The images were analyzed using OlyVIA (Olympus) and ImageJ (NIH). Percentage of area staining was used to quantify the protein expression levels in IHC slides.
Breast tumor induction in NOD scid gamma (NSG) mice
Female NSG-immunodeficient mice of 4-6 weeks old were purchased from the Jackson Laboratory. Experimental procedures and housing of the animals were approved by the Institutional Animal Care and Use Committee. Animal were housed in a fully state-of-theart facility that includes large specific pathogen free rooms, husbandry conditions (breeding program, light/dark cycle, temperature control, quality water, clean cages access to food and water), and welfare-related policies related to tumor studies (e.g., tumor burden policy).
Following power analysis, a total of 16 female mice was used, 8 for treatment, 8 for controls. For mammary pad injections, pathogen-free luciferase-expressing human breast adenocarcinoma cells (MDA-MB-231/Luc, 1-2x10 6 cells/animal) were injected into the fourth inguinal mammary gland of 6-to 8-week-old mice. Primary tumors had formed typically two weeks following cell injection. Tumor size was monitor by imaging twice a week. After experiment, mice were euthanized by isoflurane overdose (5% to effect or an overdose 100mg/kg of sodium pentobarbital), a procedure approved by our IACUC.
Ultrasound imaging of xenograft tumor in NSG mice
Details for ultrasound imaging of xenograft tumor in NSG mice have been previously reported [21] . Briefly, animals were anesthetized by exposure to 1-3% isoflurane during imaging. Imaging was performed weekly over the course of each experiment, typically for 4-6 weeks. Tumor volume was imaged by ultrasound imaging (USI) with Vevo2100 Micro-Ultrasound System. A 40 or 50 mHz transducer was used, depending on the tumor volume. 
Scratch (or "wound healing") assay
MDA-MB-231 cells were incubated in a 24-well plate. After reaching confluence, the scratch (or "wound") was created using a sterile 200-ml pipette tip, defined by the space within two red lines (upper left), filled (or "healed") by migration of cells (upper right).
Curved red line indicates the marker (shadowed area) used to identify the location of the scratch.
Caspase-3/7 Green Fluorescence Dye
CellEvent Caspase-3/7 Green Detection Reagent was obtained from Thermo Fisher (Cat#: C10723). Working solution of 1mM was used in cell culture. Fluorescence microscopy was used to acquire images. Green fluorescence was detected only apoptotic cells.
Cell cycle analysis using flow cytometry
Cells were grown to 60-80% confluency in DMEM before drug treatment. Cells were either treated with BMS-191011 in DMSO, DMSO alone, or no treatment. After 24-48 hours, cells were washed with PBS and incubated with 0.25% trypsin with EDTA (Invitrogen) for 5 minutes at 37 o C. After combining the resultant solution with 10mL PBS in 15mL tubes, cells were pelleted at 1000rpm for 6 minutes at 4 o C. Cell pellets were resuspended in 200mL PBS then added with swirling to 2mL ice cold 70% ethanol. These single-cell suspensions were kept at 4 o C until further processing.
For flow cytometry, cells were re-pelleted at 1000rpm for 6 minutes before decanting ethanol. After resuspension in 2mL PBS and incubation for 1 minute at room temperature, cells were pelleted and resuspended in 100mL of 0.2% Tween-20 in PBS at room temperature then incubated at 37 o C for 15 minutes. Next, 100mL of PBS containing 2% fetal bovine serum and 0.1% sodium azide was added and cells were pelleted. The solution was then decanted, 10mL of RNase A (DNase-and protease-free; Thermo Scientific EN0531) in PBS (180mg/mL) was added and allowed to sit for 15 minutes at room temperature, and 20mL of propidium iodide (PI) in PBS (50mg/mL) was added for 15 minutes. The resultant solution was brought to a volume of 300-500mL using PBS before data collection.
Samples were analyzed on BD LSRFortessa using BD FACS Diva version 8.0 software. A minimum of 20,000 cells were collected for each sample. Data analysis was done using FCS Express 6.0 flow cytometry software (De Novo Software, Los Angeles CA). Cell cycle fit algorithm was selected using the lowest relative chi square value and BAD value < 20%.
Statistical analysis
Data were shown as mean ± standard deviation (SD) in the text. Bar figures were presented as mean ± SD using GraphPad (Prism). Student's t-test and two-way ANOVA (for more than two groups) were used for statistical analysis. P<0.05 was considered as statistically significant. Details in statistical analysis, such as F values and degree of freedom (DF) when using ANOVA and t values when using t-test, are included in the figure legends.
Results
1) KCNMA1 gene and protein expression in breast cancer patients
We used gene expression data (RNA-seq) from 981 breast cancer samples (TCGA Cell 2015
[23] and TCGA Provisional). In all five subtypes BK channel KCNMA1 gene expression levels are dramatically upregulated, comparison to normal breast cells (FPKM ~ 0.7) (Figure 1) . TNBC patients are represented by red dots.
Using transcriptomics and a targeted proteomics approach, the gene-specific correlation of mRNA levels and protein copy number has been well established in human cells and tissues [24] . Previous studies have demonstrated that BK channel alpha subunit protein (main subunit forming the pore of the channel) is abundantly expressed in MDA-MB-231 cells, weakly expressed in MCF7, and nearly undetectable in normal breast epithelial cells MCF10A [15] . Therefore, we set out to investigate the protein expression of BK channels in TNBC patients' tissues. To confirm the increased protein expression levels of BK channels in TNBC patients, we performed IHC experiments in seven TNBC tissue and three normal breast tissue samples.
We used a BK channel antibody that had been successfully applied in identifying KCNMA1 channel protein expression in the Human Protein Atlas (Sigma-Aldrich, HPA054648). These questions led us to the hypothesis that these overexpressed BK channels are not activated. If this hypothesis is correct, then opening these channels can be exploited as a novel strategy for targeted therapy in treatment of TNBC.
For ion channels whose activity is dependent on Em, gene/protein expression levels are not intrinsically correlated with channel activity. At the resting Em of the cell, ion channels are active when they are open, inactive when they are closed. We therefore set up to investigate biophysical properties of BK channels in TNBC cells.
2) Voltage-dependent activation of BK channels in TNBC cells
Previously, we showed that the resting Em, which is within the physiological voltage range, in MDA-MB-231 cells is depolarized compared to normal mammary epithelial cells 
3) BK channel opener hyperpolarizes Em in MDA-MB-231 cells
Opening large conductance (>200pS) [29] BK channels causes loss of intracellular K + ions to the outside of the cell, leading to membrane hyperpolarization. In MDA-MB-231 cells, we used a potent selective BK channel opener, BMS-191011 (1mM) [30] to study how opening BK channels may affect cell Em. We found that BMS-191011 ( 
4) BK channel opener induced death of human TNBC cells
To test whether hyperpolarization by opening BK channels can induce death of TNBC cells, we studied effects of BK channel opener in TNBC cell lines. Treatment of BMS -191011 at 20mM for two days did not affect normal breast MCF10A cells (Supplemental Fig.3, left Fig.3 , middle panels). BMS-191011 halted growth of MCF-7 cells but induced death of much fewer cells compared to MDA-MB-231 (Supplemental Fig.3, right panels) . Figure 4A shows the percentages of dead/dying cells are 0.92 ± 0.29% (n=5) for MCF10A, 14 .76±1.94% (n=5) for MCF-7, and 63.82±6.21% (n=5) for MDA-MB-231, p<0.0001 (Oneway ANOVA).
panels), but dramatically induced cell death of MDA-MB-231 cells (Supplemental
To ensure that BMS-191011 induced cell death is via opening BK channels, we used another specific BK channel opener, NS11021, which has a different chemical structure [31] . Figure 4B shows time -and concentration -dependent effects of NS11021 on the growth of MDA-MB-231. At day 5, most cells treated with 20mM NS11021 were dead (Supplemental Fig.4 ). For the same day, NS11021 induced cell death at different concentration is statistically significant compared to untreated group (p<0.0001, n=6). Figure 7 shows an example for 0.5% DMSO (maximal volume used in drug treatment) that has no effect in cell death of HCC1143. We also tested that 
5) BK channel opener induced apoptosis and caspase-3 activation in TNBC
To understand the mechanism that mediates hyperpolarization -induced death in TNBC cells, we studied apoptosis, a well-studied programmed cell death mechanism. We performed time-lapse imaging experiment demonstrating that low concentration (1mM) of BMS-191011 induced rapid cell shrinkage, a distinguished event unique to apoptosis [34], within 20-60min (Supplemental Fig.9 ).
We also studied effect of BK channel opener in caspase activation, an established mechanism and a strong indicator of apoptosis [35] . We first used a fluorescent caspase 3/7 green dye to test whether BK channel opener may induce caspase activation in MDA-MB-231. Figure 5 shows that after 3 days of 10mM BMS-191011 treatment (5A), strong fluorescent signals (5B) were detected in MDA-MB-231. Furthermore, Figure 5C phases associated with a decrease distribution in G1 phase (B). After 48h, cells are all arrested in G2 phase (C). As a control, we showed that DMSO (1%) had no effects on cell cycle in MDA-MB-231 cells after 24h treatment (Supplemental Fig.11) . Similar results were repeated in an additional three experiments.
8) BK channel opener induced slower growth of MDA-MB-231 xenograft in NSG mice
To test the inhibitory effects of BK channel opener on TNBC tumor in vivo, we generated MDA-MB-231 xenograft in female NSG mice at 4-week old age [21] . After a sizable tumor was formed (typically after 1-2 weeks of cell injection), BMS-191011 at 100mg/kg (or 1-2mg/mouse) was directly injected into the tumor for better control of the dose and the potential loss of the drug due to rapid metabolism in mice. The drug was given twice a week in the treat group. For control group, saline was given twice a week. To avoid large variation in tumor sizes due to heterogeneity of breast cancer, we selected pairs of tumors (one as a control -injected PBS only, the other treated -injected drug in PBS) that had similar tumor sizes, and performed ultrasound imaging for four weeks to monitor effect of BK channel opener during the growth of tumors. Figure 7 shows a representative example for three pairs of control and treated tumors.
The injection of the drug began at week5 when three pairs (C1/T1, C2/T2, and C3/T3) had similar tumor sizes, the treated tumor (T) grew significantly slower than the control tumor (C) each week (7A). In week 8, averaging data showed a 33% reduction of tumor volume in drug-treated group (T= 710±105, n=8) compared to the control group (C=1056±106, n=8) (p<0.05) (7B).
9) BK channel opener and cardiac function in vivo
Cardiac toxicity is a major concern in anti-cancer drugs [38] . Supplemental Figure 12 shows the echocardiograph results for MDA-MB-231 xenograft treated mice with high dose (0.1mg/kg) of BMS-191011 compared to control (PBS treated) mice (n=3). There are no significant differences (p>0.05) between the two groups in cardiac function including heart rate, ejection fraction, left ventricular mass, and cardiac output.
Discussion
In the present work, we showed evidence to support a hypothesis that targeted treatment by activation of BK channels -thereby hyperpolarizing the Em -can induce cell death in TNBC while sparing healthy breast cells without cardiac toxicity. We selected a BK channel opener due to overexpression of the channels in breast cancer and large conductance of the channel. Opening large conductance potassium channels can effectively induce membrane hyperpolarization due to rapid efflux of K+ ions. Extremely low expression of BK channel gene expression in normal breast cells and cardiomyocytes ensures selective apoptosis in TNBC and absence of cardiac toxicity by BK channel opener.
Using microarrays, KCNMA1 gene expression was found to increase in several cancers including breast cancer [16] . Using RNA-seq data in a large breast cancer dataset in TCGA, we found overexpression of KCNMA1 in all subtypes of breast cancer. In principle, our approach of using BK opener for selective induction of cell death works for all subtypes of breast cancer. We focus on TNBC due to lack of targeted therapy in TNBC. It needs to be emphasized that mutations in KCNMA1 gene are rare -only 15 (7 in luminal A, 5 in luminal B, 2 in HER2, 1 in basal subtype) in breast cancer, although the gene is overexpressed and the cause of overexpression is unknown.
We verified that the BK channel alpha-subunit protein levels are significantly increased in We tested this concept in three TNBC cell lines, MDA-MB-231, SUM159, and HCC1143, representing different subtypes of TNBC. We used two structurally different openers (BMS-20 191011 and NS11021) to ensure that any effects seen in cell growth are mediated by BK channel opening. Notably, BK channel openers induced more cell death in MDA-MB-231 than in MCF-7 (a non-metastatic breast cancer cell line). One possible explanation is that BK channel protein levels are significantly higher in MDA-MB-231 than in MCF-7. Indeed, using immunofluorescence staining BK channels have been previously reported to be abundantly expressed in MDA-MB-231, very weak in MCF-7, and undetectable in MCF10A [15] . Additionally, we employed a constitutively opened mutant BK channel to demonstrate that hyperpolarization is the primary driving force to induce cell death in TNBC cells.
To explore cellular mechanisms that mediate the hyperpolarization-induced death in TNBC cells, we showed in MDA-MB-231 cells early morphology changes (shrinkage) and late activation of caspase-3 in MDA-MB-231 cells. Normotonic shrinkage of cells is a hallmark of apoptosis [34] . Caspase activation is a well-established pathway in apoptosis [39] . In addition, we showed that at low concentration (100nM), BK channel opener was able to prevent cell migration. A major concern in anti-cancer drugs is cardiac toxicity [38] . The KCNMA1 gene expression levels are low in the heart (FPKM 0.2 to 0.3) [40] . We performed echocardiogram on the mice to assess potential cardiac side effects of BK channel opener in cardiac functions. We found no significant changes in cardiac functions in treated mice compared to untreated mice.
Targeted therapy has significantly increased the survival rate of breast cancer patients, while it is also associated with an increased risk of cardiovascular disease (such as left ventricular dysfunction and heart failure) in breast cancer treatment [41] . For older women (>65 years) surviving breast cancer, the leading mortality is cardiovascular disease, not breast cancer itself [41] . BK channel expression levels in heart (RPKM ~0.2)
is even lower than in normal breast cells (RPKM ~0.7), targeting BK channel activation is anticipated to have significantly less effects in cardiac functions.
Conclusions
While KCNMA1 genes are overexpressed in all types of breast cancer, targeting it is particularly useful for TNBC due to lack of effective pharmacological therapy in TNBC patients. We propose a novel approach to inhibit TNBC growth based on depolarized Em and significantly increased BK channel gene expression in TNBC. This new strategy is independent of TNBC subtypes and yield tumor-specific destruction of TNBC without cardiac toxicity. 
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